Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
Open Access
- 1 July 1991
- Vol. 46 (7), 512-523
- https://doi.org/10.1136/thx.46.7.512
Abstract
No abstract availableThis publication has 93 references indexed in Scilit:
- The Isoenzyme Selectivity of AH 21–132 as an Inhibitor of Cyclic Nucleotide Phosphodiesterase ActivityJournal of Enzyme Inhibition, 1991
- High pressure liquid chromatography of cyclic nucleotide phosphodiesterase from purified human T-lymphocytesBiochemical and Biophysical Research Communications, 1989
- Electrophysiology of phosphodiesterase inhibitorsThe American Journal of Cardiology, 1989
- Invalidation of the resting electrocardiogram obtained via exercise electrode sites as a standard 12-lead recordingThe American Journal of Cardiology, 1989
- The effect of zaprinast (M&B 22,948, an orally absorbed mast cell stabilizer) on exercise-induced asthma in childrenRespiratory Medicine, 1986
- Relationships between adenosine, cyclic nucleotides, and xanthines in asthmaJournal of Allergy and Clinical Immunology, 1986
- New Positive Inotropic Agents in the Treatment of Congestive Heart FailureNew England Journal of Medicine, 1986
- Phosphodiesterase Inhibition by Ro 20-1724 Reduces Hyper-IgE Synthesis by Atopic Dermatitis Cells In VitroJournal of Investigative Dermatology, 1985
- A New Generation of Phosphodiesterase Inhibitors: Multiple Molecular Forms of Phosphodiesterase and the Potential for Drug SelectivityJournal of Medicinal Chemistry, 1985
- Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948)Respiratory Medicine, 1983